In previous studies, differential HLA binding affinities of wildtype and mutated peptides have been shown to correlate well with CD8+ T cell activation in both mouse tumor models [43] as well as in many human clinical studies [27][44][45][46]. This evidence concerns the gene CD8A and neoplasm.